Key Stats for Elevance Health Stock
- Past-Week Performance: -2%
- 52-Week Range: $273.7 to $458.8
- Current Price: $320
What Happened?
Elevance Health stock (ELV) closed at $320 just this Friday, sitting 30.2% below its 52-week high of $458.75, yet management reaffirmed its 2026 adjusted EPS guidance of at least $25.50 on February 26.
On February 26, Elevance Health’s SEC filing triggered renewed attention as the company confirmed both its adjusted EPS floor of $25.50 and its GAAP earnings floor of $22.30 for the full year.
The engine behind management’s confidence is a deliberate portfolio repositioning: Carelon Services grew nearly 60% in 2025, and CarelonRx surpassed 20% growth, partially offsetting pressure from affiliated membership declines.
Meanwhile, the market is beginning to re-rate Elevance from a pure health insurer into a diversified health services platform, as Carelon’s growing external revenue increasingly decouples from enrollment headwinds inside the health benefits segment.
CEO Gail Boudreaux stated on the Q4 earnings call that “the path isn’t predicated on a single assumption — it’s built on multiple independent levers and disciplined execution across Commercial, Medicare, Carelon and Medicaid,” framing the company’s 2027 growth target of at least 12% adjusted EPS growth as broadly supported.
Further supporting conviction, management committed to approximately $2.3 billion in share repurchases for 2026, signaling that leadership views the current $320.00 price as a compelling entry point for capital deployment.
Looking ahead, Elevance’s aggressive Carelon build-out positions the company to compete directly in health services delivery over the next three to five years, reducing its structural dependence on volatile government-program enrollment cycles.
Wall Street’s Take on X Stock
Elevance Health’s February 26 guidance reaffirmation of at least $25.50 adjusted EPS directly confirms that management’s 2026 repositioning plan remains on track despite industry-wide cost pressures.
Yet the fundamentals reveal compression: 2026 revenue is estimated at $194.9 billion, down 1.4% YoY, while normalized EPS is expected to fall 14.0% to $26.05.
Despite the earnings pressure, Wall Street maintains conviction, with 11 buys, 3 outperforms, and 8 holds among 20 analysts, and a mean price target of $387.9, implying 21.2% upside from $320.00.
The analyst target range spans $332.00 on the low end to $474.00 on the high end, with Medicaid margin recovery and Carelon’s external growth momentum serving as the key swing factors between those two outcomes.
What Does the Valuation Model Say?
TIKR’s mid-case valuation model targets $434.4 by December 2030, implying 35.7% total return and a 6.5% annualized IRR from the current $320.00 price.
The market is pricing ELV as a structurally impaired insurer, yet Carelon Services grew nearly 60% in 2025, a number inconsistent with a broken platform story.
Management committed $2.3 billion in share repurchases for 2026, signaling internal confidence that $320.00 meaningfully undervalues the enterprise.
With 11 buys still on the board and a mean target 21.2% above current levels, analysts are not abandoning conviction; they are waiting for execution to close the gap.
The real risk is Medicaid: if the projected negative 1.75% operating margin deepens further due to persistent rate-trend misalignment, the 2027 recovery thesis unravels entirely.
Watch Q1 2026 earnings for Medicaid margin and ACA effectuation rates, the two numbers that will confirm or break the trough-year narrative.
ELV is undervalued at $320.00, with a 21.2% analyst consensus upside and a clear 2027 recovery path hinging on Medicaid stabilization.
Should You Invest in Elevance Health, Inc.?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up ELV stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Elevance Health, Inc. alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze ELV stock on TIKR for Free →
